Considering that PQR309 is a pan-PI3K inhibitor, we selected isoform-specific PI3K inhibitors (BYL719 for PI3K p110α, GSK2636771 for PI3K p110β) both of which have entered clinical assessment to further compare their anti-tumor activities. Here, PIK3CA is linked to neoplasm.